Ironwood Pharmaceuticals, Inc.
IRWD
$3.73
$0.236.57%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 122.06M | 85.24M | 41.14M | 90.55M | 91.59M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 122.06M | 85.24M | 41.14M | 90.55M | 91.59M |
| Cost of Revenue | 22.47M | 23.37M | 27.43M | -78.48M | 29.83M |
| Gross Profit | 99.59M | 61.87M | 13.71M | 169.02M | 61.77M |
| SG&A Expenses | 21.91M | 16.80M | 24.26M | 33.59M | 36.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.38M | 40.17M | 51.69M | 58.98M | 65.94M |
| Operating Income | 77.68M | 45.07M | -10.55M | 31.56M | 25.65M |
| Income Before Tax | 68.02M | 37.82M | -36.27M | 24.00M | 17.37M |
| Income Tax Expenses | 27.94M | 14.22M | 1.11M | 21.74M | 13.72M |
| Earnings from Continuing Operations | 40.08M | 23.60M | -37.39M | 2.26M | 3.65M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.08M | 23.60M | -37.39M | 2.26M | 3.65M |
| EBIT | 77.68M | 45.07M | -10.55M | 31.56M | 25.65M |
| EBITDA | 78.16M | 45.54M | -10.07M | 32.05M | 26.16M |
| EPS Basic | 0.25 | 0.15 | -0.23 | 0.01 | 0.02 |
| Normalized Basic EPS | 0.27 | 0.15 | -0.07 | 0.09 | 0.07 |
| EPS Diluted | 0.23 | 0.14 | -0.23 | 0.01 | 0.02 |
| Normalized Diluted EPS | 0.25 | 0.13 | -0.07 | 0.09 | 0.07 |
| Average Basic Shares Outstanding | 162.22M | 161.72M | 160.97M | 159.45M | 159.71M |
| Average Diluted Shares Outstanding | 177.76M | 176.84M | 160.97M | 159.45M | 160.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |